COSCIENS Biopharma Inc (CSCI)

[livendi]

its been a rough ride down to 70 cents but medium to longterm u cannot and will not lose,compare all the different catalysts aezs has now compared to when klauss 1st took over,im more confident than ever with aezs because of all the different catalysts coming and some are for unmet needs,like pedi approval for test,70 mill in the bank and a very low burn rate,ive bought more with this recent drop,aezs is way underpriced considering what they have coming,all u have to do is hold and dont forget about the 2 phase 3 trials in usa for macrilen treating tbi and cancer cachexia,again just hold,god bless all and good luck to us